Latest & greatest articles for mirtazapine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on mirtazapine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on mirtazapine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for mirtazapine

1. Combining mirtazapine with other antidepressants is not effective for treatment-resistant depression

Combining mirtazapine with other antidepressants is not effective for treatment-resistant depression Combining mirtazapine with other antidepressants is not effective for treatment-resistant depression Discover Portal Discover Portal Combining mirtazapine with other antidepressants is not effective for treatment-resistant depression Published on 15 January 2019 doi: Adding mirtazapine to first-line antidepressants for adults with treatment-resistant depression does not improve symptoms when (...) compared with placebo (dummy pills). People taking mirtazapine are more likely to experience side effects, and stop taking their treatment. This NIHR-funded trial took place in 106 general practices in England, recruiting 480 adults with mild to severe depression. All participants had been taking selective serotonin reuptake inhibitor (SSRI) or serotonin-noradrenaline reuptake inhibitor (SNRI) antidepressants for at least six weeks but were still depressed. The findings show that this combination has

2019 NIHR Dissemination Centre

2. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). (PubMed)

Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). To investigate the effectiveness of combining mirtazapine with serotonin-noradrenaline reuptake inhibitor (SNRI) or selective serotonin reuptake inhibitor (SSRI) antidepressants for treatment resistant depression in primary care.Two parallel group multicentre phase III randomised placebo controlled trial.106 general practices in four UK sites; Bristol (...) , Exeter, Hull, and Keele/North Staffs, August 2013 to October 2015.480 adults aged 18 or more years who scored 14 or more on the Beck depression inventory, second revision, fulfilled ICD-10 (international classification of diseases, 10th revision) criteria for depression, and had used an SSRI or SNRI for at least six weeks but were still depressed. 241 were randomised to mirtazapine and 239 to placebo, both given in addition to usual SSRI or SNRI treatment. Participants were stratified by centre

Full Text available with Trip Pro

2018 BMJ

3. Mirtazapine for fibromyalgia in adults. (PubMed)

Mirtazapine for fibromyalgia in adults. Fibromyalgia is a clinically defined chronic condition of unknown etiology characterised by chronic widespread pain, sleep disturbance, cognitive dysfunction, and fatigue. Many patients report high disability levels and poor quality of life. Drug therapy aims to reduce key symptoms, especially pain, and improve quality of life. The tetracyclic antidepressant, mirtazapine, may help by increasing serotonin and noradrenaline in the central nervous system (...) (CNS).To assess the efficacy, tolerability and safety of the tetracyclic antidepressant, mirtazapine, compared with placebo or other active drug(s) in the treatment of fibromyalgia in adults.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, SCOPUS, the US National Institutes of Health, and the World Health Organization (WHO) International Clinical Trials Registry Platform for published and ongoing trials, and examined reference lists of reviewed articles

2018 Cochrane

4. Mirtazapine

Mirtazapine Top results for mirtazapine - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for mirtazapine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

5. Mirtazapine adjunct for people with schizophrenia. (PubMed)

Mirtazapine adjunct for people with schizophrenia. Many individuals who have a diagnosis of schizophrenia experience a range of distressing and debilitating symptoms. These can include positive symptoms (such as delusions, hallucinations, disorganised speech), cognitive symptoms (such as trouble focusing or paying attention or using information to make decisions), and negative symptoms (such as diminished emotional expression, avolition, alogia, and anhedonia). Antipsychotic drugs are often (...) only partially effective, particularly in treating negative symptoms, indicating the need for additional treatment. Mirtazapine is an antidepressant drug that when taken in addition to an antipsychotic may offer some benefit for negative symptoms.To systematically assess the effects of mirtazapine as adjunct treatment for people with schizophrenia.The Information Specialist of Cochrane Schizophrenia searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (including registries

2018 Cochrane

6. The Risk of Hip Fracture Due to Mirtazapine Exposure When Switching Antidepressants or Using Other Antidepressants as Add-On Therapy (PubMed)

The Risk of Hip Fracture Due to Mirtazapine Exposure When Switching Antidepressants or Using Other Antidepressants as Add-On Therapy Antidepressants are associated with adverse effects such as sedation and hypotension, which can result in falls and fractures. Few studies have assessed the risk of hip fracture due to mirtazapine, and no known studies have assessed whether the risk of hip fracture is higher in patients taking other antidepressant medicines in combination with mirtazapine.This (...) study aimed to examine the risk of hip fracture in older people due to mirtazapine use as well as switching between or concurrently using mirtazapine and other antidepressants.A matched case-control study was conducted. Cases were people aged over 65 years who were eligible for Australian Government Department of Veterans' Affairs (DVA) benefits and who sustained a hip fracture between 2009 and 2012. Each case was matched with up to four randomly selected controls of the same gender and age (± 2

Full Text available with Trip Pro

2017 Drugs - real world outcomes

7. Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments Kosten-nutzen-bewertung von venlafaxin, duloxetin, bupropion und mirtazapin im vergleich zu weiteren verordnungsfähigen medika-mentösen behandlungen [Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments] Kosten-nutzen-bewertung von venlafaxin, duloxetin, bupropion und (...) mirtazapin im vergleich zu weiteren verordnungsfähigen medika-mentösen behandlungen [Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Kosten-nutzen-bewertung von venlafaxin, duloxetin, bupropion

2014 Health Technology Assessment (HTA) Database.

8. Mirtazapine

Mirtazapine USE OF MIRTAZAPINE IN PREGNANCY 0344 892 0909 USE OF MIRTAZAPINE IN PREGNANCY (Date of issue: September 2015 , Version: 2.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Mirtazapine is a benzazepine tetracyclic antidepressant (...) licensed for use in the treatment of depression and mood disorders. It is also used off-licence in the treatment of anxiety and as an antiemetic. Its mechanism of action is related to that of selective-serotonin reuptake inhibitors (SSRIs). The data regarding exposure to mirtazapine in human pregnancy are limited and comprises around 700 exposures, derived from case reports, case series, cohort studies and registry studies. Use of mirtazapine in pregnancy should therefore be limited to situations where

2014 UK Teratology Information Service

9. Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial

Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial Romeo R, Knapp M, Hellier J, Dewey M, Ballard C, Baldwin R, Bentham P, Burns A, Fox C, Holmes C, Katona C, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, O'Brien J (...) , Poppe M, Thomas A, Walwyn R, Wilson K, Banerjee S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of sertraline and mirtazapine, for the treatment of depression, in patients

Full Text available with Trip Pro

2013 NHS Economic Evaluation Database.

10. Efficacy and tolerability of mirtazapine versus paroxetine in the treatment of major depressive disorder

Efficacy and tolerability of mirtazapine versus paroxetine in the treatment of major depressive disorder Efficacy and tolerability of mirtazapine versus paroxetine in the treatment of major depressive disorder Efficacy and tolerability of mirtazapine versus paroxetine in the treatment of major depressive disorder Gonzalez Rodriguez A, Gasto Ferrer C, Navarro Odriozola V CRD summary The authors concluded that mirtazapine was effective earlier, but at six to eight weeks, paroxetine was equally (...) effective for the treatment of major depressive disorder. There were some methodological limitations, and no validity assessment, leaving the reliability of the conclusions uncertain. Authors' objectives To compare the efficacy and tolerability of paroxetine with those of mirtazapine for the treatment of major depressive disorder. Searching PubMed and PsycINFO were searched for articles from 1980 to June 2011; search terms were reported. It appears that published systematic reviews were checked

Full Text available with Trip Pro

2013 DARE.

11. Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments Executive Summary 1 Translation of the executive summary of the final report “Kosten-Nutzen-Bewertung von Venlafaxin, Duloxetin, Bupropion und Mirtazapin im Vergleich zu weiteren verordnungsfähigen medikamentösen Behandlungen” (Version 1.0; Status: 3 September 2013). Please note: This translation is provided as a service by IQWiG to English-language (...) readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. G09-01 Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments 1 Executive summary of final report G09-01 Version 1.0 Health economic evaluation of venlafaxine, duloxetine, bupropion, mirtazapine 3 Sep 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

12. Sertraline and mirtazapine do not reduce severity of depression in people with dementia

Sertraline and mirtazapine do not reduce severity of depression in people with dementia Sertraline and mirtazapine do not reduce severity of depression in people with dementia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Sertraline and mirtazapine do not reduce severity of depression in people with dementia Article Text Therapeutics Sertraline and mirtazapine do not reduce severity of depression in people with dementia Statistics from

2012 Evidence-Based Mental Health

13. Mirtazapine to reduce methamphetamine use: a randomized controlled trial (PubMed)

Mirtazapine to reduce methamphetamine use: a randomized controlled trial No approved pharmacologic treatments for methamphetamine dependence exist. Methamphetamine use is associated with high morbidity and is a major cofactor in the human immunodeficiency virus epidemic among men who have sex with men (MSM).To determine whether mirtazapine would reduce methamphetamine use among MSM who are actively using methamphetamine.Double-blind, randomized, controlled, 12-week trial of mirtazapine vs (...) placebo conducted from September 5, 2007, to March 4, 2010.San Francisco Department of Public Health.Participants were actively using, methamphetamine-dependent, sexually active MSM seen weekly for urine sample collection and substance use counseling.Random assignment to daily oral mirtazapine (30 mg) or placebo; both arms included 30-minute weekly substance use counseling.The primary study outcome was reduction in methamphetamine-positive urine test results. Secondary outcomes were study medication

Full Text available with Trip Pro

2011 EvidenceUpdates

14. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial (PubMed)

Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial Prominent anxiety symptoms are related to poor clinical course and outcome in major depressive disorder (MDD). The aim of this randomised, open-label, controlled study is to compare the efficacy and tolerability of mirtazapine in the form of orally disintegrating tablets against paroxetine in treating MDD patients with anxiety (...) symptoms.A total of 60 MDD patients with a score above 18 on the Hamilton Anxiety Rating Scale (HARS) were randomly assigned to 8 weeks of fixed dosing treatment with mirtazapine (15-30 mg/day) and paroxetine (10-20 mg/day). Efficacy was primarily assessed with the HARS and with the 17-item Hamilton Depression Rating Scale (HDRS) at weeks 1, 2, 4 and 8 after treatment. Tolerability was assessed from adverse events.The generalised estimating equations (GEE) models showed that the rates of improvement

2011 EvidenceUpdates

15. Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.1

Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.1 Executive Summary IQWiG Reports – Commission No. A05-20C Bupropion, mirtazapine, and reboxetine in the treatment of depression 1 1 Translation of the executive summary of the final report “Bupropion, Mirtazapin und Reboxetin bei der Behandlung der Depression” (Version 1.1; Status: 30.05.2011). Please note that this translation is provided as a service by IQWiG to English-language readers. However, solely (...) the German original text is absolutely authoritative and legally binding. Executive summary of final report A05-20C Bupropion, mirtazapine, and reboxetine in depression 30.05.2011 Institute for Quality and Efficiency in Health Care (IQWiG) Version 1.1 - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Bupropion, mirtazapine, and reboxetine in the treatment of depression Contracting agency: Federal Joint Committee Commission awarded on: 22.02.2005 Internal

2011 Institute for Quality and Efficiency in Healthcare (IQWiG)

16. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. (PubMed)

Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Depression is common in dementia but the evidence base for appropriate drug treatment is sparse and equivocal. We aimed to assess efficacy and safety of two of the most commonly prescribed drugs, sertraline and mirtazapine, compared with placebo.We undertook the parallel-group, double-blind, placebo-controlled, Health Technology Assessment Study of the Use (...) unit at King's College London (UK) randomly allocated participants with a computer-generated block randomisation sequence, stratified by centre, with varying block sizes, in a 1:1:1 ratio to receive sertraline (target dose 150 mg per day), mirtazapine (45 mg), or placebo (control group), all with standard care. The primary outcome was reduction in depression (CSDD score) at 13 weeks (outcomes to 39 weeks were also assessed), assessed with a mixed linear-regression model adjusted for baseline CSDD

Full Text available with Trip Pro

2011 Lancet

17. Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder

Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any (...) time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine

2010 Evidence-Based Mental Health

18. Megestrol acetate and mirtazapine for the treatment of unplanned weight loss in the elderly (PubMed)

Megestrol acetate and mirtazapine for the treatment of unplanned weight loss in the elderly A rising concern among clinicians is treatment of unplanned weight loss in the elderly, especially given the predicted growth of this population over the next few decades. Unexpected weight loss in the geriatric patient worsens overall health outcomes. A variety of pharmacotherapeutic options are available for treatment; however, evidence underlying their use is limited, and none has gained approval from (...) the United States Food and Drug Administration for this indication. At present, no guidelines support the choice of one agent over another. Although several drug interventions have been employed for this problem, megestrol acetate and mirtazapine are becoming increasingly used for appetite stimulation. These drugs represent two feasible options for geriatric patients because of their generally favorable adverse-effect profiles and few drug interactions, but they are often misused. In a comprehensive

2009 EvidenceUpdates

19. Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.0

Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.0 Executive Summary IQWiG Reports – Commission No. A05-20C Bupropion, mirtazapine, and reboxetine in the treatment of depression 1 1 Translation of the executive summary of the final report “Bupropion, Mirtazapin und Reboxetin bei der Behandlung der Depression” (Version 1.0; Status: 09.11.2009). Please note that this translation is provided as a service by IQWiG to English-language readers. However, solely (...) the German original text is absolutely authoritative and legally binding. Executive summary of final report A05-20C Bupropion, mirtazapine, and reboxetine in depression Version 1.0 09.11.2009 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Bupropion, mirtazapine, and reboxetine in the treatment of depression Contracting agency: Federal Joint Committee Commission awarded on: 22.02.2005 Internal Commission No.: A05-20C Publisher’s address: Institute for Quality

2009 Institute for Quality and Efficiency in Healthcare (IQWiG)

20. Mirtazapine and nortriptyline similarly effective third-line treatments for depression

Mirtazapine and nortriptyline similarly effective third-line treatments for depression Mirtazapine and nortriptyline similarly effective third-line treatments for depression | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Mirtazapine and nortriptyline similarly effective third-line treatments for depression Article Text Therapeutics Mirtazapine and nortriptyline similarly effective third-line treatments for depression Statistics from

2008 Evidence-Based Mental Health